Ann: Opthea Completes Enrollment in Phase 3 Clinical Program, page-21

That is my thinking as well. The Phase 2b trial with over 300 participants (not 30) went very well, and moving to 900 in Phase 3 with a nearly identical protocol is, mathematically speaking, almost a sure thing mathematically speaking to see a reproduction of the Phase 2b results in Phase 3. So, the risk sits outside of mathematical predictions

As many here have mentioned, there are no sure bets in Phase 3 trials, but I am at a loss as to what the high-IQ analysts internally at the big pharma could be imagining. Or perhaps OPT has rejected their multibillion-dollar advances.

Certainly, I'm thinking of big buy if OPT's stock gets into the 40s.

Interesting speculation that a low stock price may force OPT's hand into accepting a bad deal as the possibility of a CR is diminished.